ArticleJournal of diabetes investigation2026
Insulin-reducing effect of adding imeglimin to ongoing dipeptidyl peptidase-4 inhibitor therapy with multiple daily insulin injections (INSPIRE study).
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSimplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase-4 inhibitors (DPP-4i), its effectiveness in patients treated with MDI remains unclear. This study aimed to investigate the real-world characteristics of such patients and the insulin-reducing effects of adding imeglimin to ongoing DPP-4i therapy. MATERIALS AND
methodsMedical records of inpatients with type 2 diabetes (T2D) treated with imeglimin (2,000 mg/day) plus DPP-4i and MDI were reviewed. Insulin dosage and self-monitoring blood glucose (SMBG) values were compared between baseline and 5 days post-imeglimin initiation. Patients were divided into bolus-discontinuation (bolus insulin discontinued) and bolus-continuation (bolus insulin continued) groups, and baseline characteristics were compared. The correlation between the reduction in bolus insulin (Δ bolus) and baseline parameters was assessed.
resultsThirty patients (18 males and 12 females) were enrolled. Mean values were: age, 77.7 years; duration of T2D, 14.2 years; BMI, 21.6 kg/m
conclusionAdding imeglimin to DPP-4i significantly reduced insulin dosage, even in patients with low insulin secretory capacity. This combination may represent a useful therapeutic option for Japanese patients with T2D treated with MDI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.